<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38249443</PMID><DateCompleted><Year>2024</Year><Month>01</Month><Day>23</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1750-2659</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Influenza and other respiratory viruses</Title><ISOAbbreviation>Influenza Other Respir Viruses</ISOAbbreviation></Journal><ArticleTitle>Comparative analysis of mortality in patients admitted with an infection with influenza A/B virus, respiratory syncytial virus, rhinovirus, metapneumovirus or SARS-CoV-2.</ArticleTitle><Pagination><StartPage>e13237</StartPage><MedlinePgn>e13237</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e13237</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1111/irv.13237</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">While influenza virus and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are recognised as a cause of severe illness and mortality, clinical interest for respiratory syncytial virus (RSV), rhinovirus and human metapneumovirus (hMPV) infections is still limited.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We conducted a retrospective database study comparing baseline characteristics and 30-day mortality in a large cohort of adult patients admitted for an overnight stay or longer with an influenza virus (A/B), rhinovirus, hMPV, RSV or SARS-CoV-2 infection. For non-SARS-CoV-2 viruses, data were included for the period July 2017-February 2020. For SARS-CoV-2, data between March 2020 and March 2022 were included.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Covariate-adjusted 30-day mortality following RSV, hMPV or rhinovirus infections was substantial (crude mortality 8-10%) and comparable with mortality following hospitalisation with an influenza A virus infection. Mortality following a SARS-CoV-2 infection was consistently higher than for any other respiratory virus, at any point in time (crude mortality 14-25%). Odds of mortality for SARS-CoV-2 compared with influenza A declined from 4.9 to 1.7 over the course of the pandemic. Patients with SARS-CoV-2 infection had less comorbidity than patients with other respiratory virus infections and were more often male. In this cohort, age was related to mortality following hospitalisation, while an association with comorbidity was not apparent.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">With the exception of SARS-CoV-2 infections, we find the clinical outcome of common respiratory virus infections requiring hospitalisation more similar than often assumed. The observed mortality from SARS-CoV-2 was significantly higher, but the difference with other respiratory viruses became less distinct over time.</AbstractText><CopyrightInformation>© 2024 The Authors. Influenza and Other Respiratory Viruses published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Boon</LastName><ForeName>Hanneke</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-4235-0634</Identifier><AffiliationInfo><Affiliation>Department of Medical Microbiology and Immunology St. Antonius Hospital the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meinders</LastName><ForeName>Arend-Jan</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine St. Antonius Hospital the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Intensive Care Unit St. Antonius Hospital the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Hannen</LastName><ForeName>Erik Jan</ForeName><Initials>EJ</Initials><AffiliationInfo><Affiliation>Department of Medical Microbiology and Immunology St. Antonius Hospital the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tersmette</LastName><ForeName>Matthijs</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medical Microbiology and Immunology St. Antonius Hospital the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schaftenaar</LastName><ForeName>Erik</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Medical Microbiology and Immunology St. Antonius Hospital the Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>01</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Influenza Other Respir Viruses</MedlineTA><NlmUniqueID>101304007</NlmUniqueID><ISSNLinking>1750-2640</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029121" MajorTopicYN="Y">Metapneumovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012229" MajorTopicYN="N">Rhinovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009981" MajorTopicYN="N">Influenza B virus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009980" MajorTopicYN="Y">Influenza A virus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="Y">Influenza, Human</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018113" MajorTopicYN="Y">Respiratory Syncytial Virus, Human</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="Y">Enterovirus Infections</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS‐CoV‐2</Keyword><Keyword MajorTopicYN="N">influenza</Keyword><Keyword MajorTopicYN="N">metapneumovirus</Keyword><Keyword MajorTopicYN="N">mortality</Keyword><Keyword MajorTopicYN="N">respiratory syncytial virus</Keyword><Keyword MajorTopicYN="N">rhinovirus</Keyword></KeywordList><CoiStatement>The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. No external funding was received to conduct this study.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>5</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>11</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>11</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>1</Month><Day>23</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>1</Month><Day>22</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>1</Month><Day>22</Day><Hour>4</Hour><Minute>55</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>1</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38249443</ArticleId><ArticleId IdType="pmc">PMC10796251</ArticleId><ArticleId IdType="doi">10.1111/irv.13237</ArticleId><ArticleId IdType="pii">IRV13237</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Naghavi M, Abajobir AA, Abbafati C, et al. Global, regional, and national age‐sex specifc mortality for 264 causes of death, 1980‐2016: a systematic analysis for the global burden of disease study 2016. Lancet. 2017;390(10100):1151‐1210. doi:10.1016/S0140-6736(17)32152-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(17)32152-9</ArticleId><ArticleId IdType="pmc">PMC5605883</ArticleId><ArticleId IdType="pubmed">28919116</ArticleId></ArticleIdList></Reference><Reference><Citation>Vestergaard LS, Nielsen J, Krause TG, et al. Excess all‐cause and influenza‐attributable mortality in Europe, December 2016 to February 2017. Eurosurveillance. 2017;22(14). doi:10.2807/1560-7917.ES.2017.22.14.30506</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2017.22.14.30506</ArticleId><ArticleId IdType="pmc">PMC5388126</ArticleId><ArticleId IdType="pubmed">28424146</ArticleId></ArticleIdList></Reference><Reference><Citation>Nielsen J, Vestergaard LS, Richter L, et al. European all‐cause excess and influenza‐attributable mortality in the 2017/18 season: should the burden of influenza B be reconsidered? Clin Microbiol Infect. 2019;25(10):1266‐1276. doi:10.1016/j.cmi.2019.02.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2019.02.011</ArticleId><ArticleId IdType="pubmed">30790685</ArticleId></ArticleIdList></Reference><Reference><Citation>Falsey A, Hennessey P, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and high‐risk adults. NEJM. 2005;352(17):77‐1759. doi:10.1056/NEJMoa043951</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa043951</ArticleId><ArticleId IdType="pubmed">15858184</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee N, Smith S, Zelyas N, et al. Burden of noninfluenza respiratory viral infections in adults admitted to hospital: analysis of a multiyear Canadian surveillance cohort from 2 centres. CMAJ. 2021;193(13):E439‐E446. doi:10.1503/cmaj.201748</Citation><ArticleIdList><ArticleId IdType="doi">10.1503/cmaj.201748</ArticleId><ArticleId IdType="pmc">PMC8099164</ArticleId><ArticleId IdType="pubmed">33782171</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludwig M, Jacob J, Basedow F, Andersohn F, Walker J. Clinical outcomes and characteristics of patients hospitalized for influenza or COVID‐19 in Germany. IJID. 2021;103:316‐322. doi:10.1016/j.ijid.2020.11.204</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2020.11.204</ArticleId><ArticleId IdType="pmc">PMC7774009</ArticleId><ArticleId IdType="pubmed">33279652</ArticleId></ArticleIdList></Reference><Reference><Citation>Fröhlich GM, de Kraker MEA, Abbas M, et al. Hospital outcomes of community‐acquired COVID‐19 versus influenza: insights from the Swiss hospital‐based surveillance of influenza and COVID‐19. Eurosurveillance. 2022;27(1). doi:10.2807/1560-7917.ES.2022.27.1.2001848</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2022.27.1.2001848</ArticleId><ArticleId IdType="pmc">PMC8739338</ArticleId><ArticleId IdType="pubmed">34991775</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia Y, Ma H, Buckeridge DL, et al. Mortality trends and length of stays among hospitalized patients with COVID‐19 in Ontario and Québec (Canada): a population‐based cohort study of the first three epidemic waves. IJID. 2022;121:1‐10. doi:10.1016/j.ijid.2022.04.048</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2022.04.048</ArticleId><ArticleId IdType="pmc">PMC9040412</ArticleId><ArticleId IdType="pubmed">35477050</ArticleId></ArticleIdList></Reference><Reference><Citation>Bechman K, Yates M, Mann K, et al. Inpatient COVID‐19 mortality has reduced over time: results from an observational cohort. PLoS ONE. 2022;17(1):e0261142. doi:10.1371/journal.pone.0261142</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0261142</ArticleId><ArticleId IdType="pmc">PMC8757902</ArticleId><ArticleId IdType="pubmed">35025917</ArticleId></ArticleIdList></Reference><Reference><Citation>Veneti L, Bøås H, Bråthen Kristoffersen A, et al. Reduced risk of hospitalisation among reported COVID‐19 cases infected with the SARS‐CoV‐2 omicron BA.1 variant compared with the Delta variant, Norway, December 2021 to January 2022. Eurosurveillance. 2022;27(4). doi:10.2807/1560-7917.ES.2022.27.4.2200077</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2022.27.4.2200077</ArticleId><ArticleId IdType="pmc">PMC8796289</ArticleId><ArticleId IdType="pubmed">35086614</ArticleId></ArticleIdList></Reference><Reference><Citation>van Summeren J, Meijer A, Aspelund G, et al. Low levels of respiratory syncytial virus activity in Europe during the 2020/21 season: what can we expect in the coming summer and autumn/winter? Eurosurveillance. 2021;26(29). doi:10.2807/1560-7917.ES.2021.26.29.2100639</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2021.26.29.2100639</ArticleId><ArticleId IdType="pmc">PMC8299745</ArticleId><ArticleId IdType="pubmed">34296672</ArticleId></ArticleIdList></Reference><Reference><Citation>Billard MN, van de Ven PM, Baraldi B, Kragten‐Tabatabaie L, Bont LJ, Wildenbeest JG. International changes in respiratory syncytial virus (RSV) epidemiology during the COVID‐19 pandemic: association with school closures. Influ Other Respir Viruses. 2022;16(5):926‐936. doi:10.1111/irv.12998</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/irv.12998</ArticleId><ArticleId IdType="pmc">PMC9343326</ArticleId><ArticleId IdType="pubmed">35733362</ArticleId></ArticleIdList></Reference><Reference><Citation>Larrauri A, Trilar KP. Preparing for an influenza season 2021/22 with a likely co‐circulation of influenza virus and SARS‐CoV‐2. Eurosurveillance. 2021;26(41). doi:10.2807/1560-7917.ES.2021.26.41.2100975</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2021.26.41.2100975</ArticleId><ArticleId IdType="pmc">PMC8518305</ArticleId><ArticleId IdType="pubmed">34651574</ArticleId></ArticleIdList></Reference><Reference><Citation>Maertzdorf J, Wang CK, Brown JB, et al. Real‐time reverse transcriptase PCR assay for detection of human Metapneumoviruses from all known genetic lineages. J Clin Microbiol. 2004;42(3):981‐986. doi:10.1128/JCM.42.3.981-986.2004</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.42.3.981-986.2004</ArticleId><ArticleId IdType="pmc">PMC356857</ArticleId><ArticleId IdType="pubmed">15004041</ArticleId></ArticleIdList></Reference><Reference><Citation>Corman VM, Landt O, Kaiser M, et al. Detection of 2019 novel coronavirus (2019‐nCoV) by real‐time RT‐PCR. Eurosurveillance. 2020;25(3):1. doi:10.2807/1560-7917.ES.2020.25.3.2000045</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2020.25.3.2000045</ArticleId><ArticleId IdType="pmc">PMC6988269</ArticleId><ArticleId IdType="pubmed">31992387</ArticleId></ArticleIdList></Reference><Reference><Citation>Quan H, Li B, Couris CM, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676‐682. doi:10.1093/aje/kwq433</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kwq433</ArticleId><ArticleId IdType="pubmed">21330339</ArticleId></ArticleIdList></Reference><Reference><Citation>R Core Team . R: A language and environment for statistical computing. 2021.</Citation></Reference><Reference><Citation>Ackerson B, Tseng HF, Sy LS, et al. Severe morbidity and mortality associated with respiratory syncytial virus versus influenza infection in hospitalized older adults. Clin Infect Dis. 2019;69(2):197‐203. doi:10.1093/cid/ciy991</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciy991</ArticleId><ArticleId IdType="pmc">PMC6603263</ArticleId><ArticleId IdType="pubmed">30452608</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimmerman RK, Balasubramani GK, D'Agostino HEA, et al. Population‐based hospitalization burden estimates for respiratory viruses, 2015‐2019. Influ Other Respir Viruses. 2022;16(6):1133‐1140. doi:10.1111/irv.13040</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/irv.13040</ArticleId><ArticleId IdType="pmc">PMC9530548</ArticleId><ArticleId IdType="pubmed">35996836</ArticleId></ArticleIdList></Reference><Reference><Citation>van Asten L, van den Wijngaard C, van Pelt W, et al. Mortality attributable to 9 common infections: significant effect of influenza a, respiratory syncytial virus, influenza B, norovirus, and parainfluenza in elderly persons. J Infect Dis. 2012;206(5):628‐639. doi:10.1093/infdis/jis415</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jis415</ArticleId><ArticleId IdType="pubmed">22723641</ArticleId></ArticleIdList></Reference><Reference><Citation>Hedberg P, Karlsson Valik J, van der Werff S, et al. Clinical phenotypes and outcomes of SARS‐CoV‐2, influenza, RSV and seven other respiratory viruses: a retrospective study using complete hospital data. Thorax. 2022;77(2):1‐10. doi:10.1136/thoraxjnl-2021-216949</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thoraxjnl-2021-216949</ArticleId><ArticleId IdType="pmc">PMC8260304</ArticleId><ArticleId IdType="pubmed">34226206</ArticleId></ArticleIdList></Reference><Reference><Citation>Piroth L, Cottenet J, Mariet AS, et al. Comparison of the characteristics, morbidity, and mortality of COVID‐19 and seasonal influenza: a nationwide, population‐based retrospective cohort study. Lancet Respir Med. 2021;9(3):251‐259. doi:10.1016/S2213-2600(20)30527-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(20)30527-0</ArticleId><ArticleId IdType="pmc">PMC7832247</ArticleId><ArticleId IdType="pubmed">33341155</ArticleId></ArticleIdList></Reference><Reference><Citation>The FLUVAC Study Group , Bénézit F, Loubet P, et al. Non‐influenza respiratory viruses in adult patients admitted with influenza‐like illness: a 3‐year prospective multicenter study. Infection. 2020;48(4):489‐495. doi:10.1007/s15010-019-01388-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s15010-019-01388-1</ArticleId><ArticleId IdType="pmc">PMC7095392</ArticleId><ArticleId IdType="pubmed">32056143</ArticleId></ArticleIdList></Reference><Reference><Citation>Branche AR, Saiman L, Walsh EE, et al. Incidence of respiratory syncytial virus infection among hospitalized adults, 2017‐2020. Clin Infect Dis. 2022;74(6):1004‐1011. doi:10.1093/cid/ciab595</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab595</ArticleId><ArticleId IdType="pubmed">34244735</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamilton MA, Liu Y, Calzavara A, et al. Predictors of all‐cause mortality among patients hospitalized with influenza, respiratory syncytial virus, or SARS‐CoV‐2. Influ Other Respir Viruses. 2022;16(6):1072‐1081.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9347457</ArticleId><ArticleId IdType="pubmed">35611399</ArticleId></ArticleIdList></Reference><Reference><Citation>Reacher M, Warne B, Reeve L, et al. Influenza‐associated mortality in hospital care: a retrospective cohort study of risk factors and impact of oseltamivir in an English teaching hospital, 2016 to 2017. Eurosurveillance. 2019;24(44). doi:10.2807/1560-7917.ES.2019.24.44.1900087</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2019.24.44.1900087</ArticleId><ArticleId IdType="pmc">PMC6836682</ArticleId><ArticleId IdType="pubmed">31690364</ArticleId></ArticleIdList></Reference><Reference><Citation>Mertz D, Kim TH, Johnstone J, et al. Populations at risk for severe or complicated influenza illness: systematic review and meta‐analysis. BMJ. 2013;347(aug23 1):f5061. doi:10.1136/bmj.f5061</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.f5061</ArticleId><ArticleId IdType="pmc">PMC3805492</ArticleId><ArticleId IdType="pubmed">23974637</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsunaga N, Hayakawa K, Asai Y, et al. Clinical characteristics of the first three waves of hospitalised patients with COVID‐19 in Japan prior to the widespread use of vaccination: a nationwide observational study. Lancet Reg Heal West Pacific. 2022;22jou:100421. doi:10.1016/j.lanwpc.2022.100421</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanwpc.2022.100421</ArticleId><ArticleId IdType="pmc">PMC8923875</ArticleId><ArticleId IdType="pubmed">35300186</ArticleId></ArticleIdList></Reference><Reference><Citation>Nyberg T, Ferguson NM, Nash SG, et al. Comparative analysis of the risks of hospitalisation and death associated with SARS‐CoV‐2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. Lancet. 2022;399(10332):1303‐1312. doi:10.1016/S0140-6736(22)00462-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00462-7</ArticleId><ArticleId IdType="pmc">PMC8926413</ArticleId><ArticleId IdType="pubmed">35305296</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong C, Zhang HG, L'Yi S, et al. Changes in laboratory value improvement and mortality rates over the course of the pandemic: an international retrospective cohort study of hospitalised patients infected with SARS‐CoV‐2 the consortium for clinical characterization of COVID‐19 by EHR (4CE). BMJ Open. 2022;12(6):57725. doi:10.1136/bmjopen-2021-057725</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2021-057725</ArticleId><ArticleId IdType="pmc">PMC9226470</ArticleId><ArticleId IdType="pubmed">35738646</ArticleId></ArticleIdList></Reference><Reference><Citation>Strålin K, Wahlström E, Walther S, et al. Mortality in hospitalized COVID‐19 patients was associated with the COVID‐19 admission rate during the first year of the pandemic in Sweden. Infect Dis (Auckl). 2022;54(2):145‐151. doi:10.1080/23744235.2021.1983643</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/23744235.2021.1983643</ArticleId><ArticleId IdType="pubmed">34612774</ArticleId></ArticleIdList></Reference><Reference><Citation>Freeman A, Watson A, O'Regan P, et al. Wave comparisons of clinical characteristics and outcomes of COVID‐19 admissions‐exploring the impact of treatment and strain dynamics. J Clin Virol. 2022;146:1386, 105031‐6532. doi:10.1016/j.jcv.2021.105031</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2021.105031</ArticleId><ArticleId IdType="pmc">PMC8608665</ArticleId><ArticleId IdType="pubmed">34844145</ArticleId></ArticleIdList></Reference><Reference><Citation>Dongelmans DA, Termorshuizen F, Brinkman S, et al. Characteristics and outcome of COVID‐19 patients admitted to the ICU: a nationwide cohort study on the comparison between the first and the consecutive upsurges of the second wave of the COVID‐19 pandemic in the Netherlands. Ann Intensive Care. 2022;12(1):5. doi:10.1186/s13613-021-00978-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13613-021-00978-3</ArticleId><ArticleId IdType="pmc">PMC8755895</ArticleId><ArticleId IdType="pubmed">35024981</ArticleId></ArticleIdList></Reference><Reference><Citation>Challen R, Brooks‐Pollock E, Read JM, Dyson L, Tsaneva‐Atanasova K, Danon L. Risk of mortality in patients infected with SARS‐CoV‐2 variant of concern 202012/1: matched cohort study. BMJ. 2021;372.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7941603</ArticleId><ArticleId IdType="pubmed">33687922</ArticleId></ArticleIdList></Reference><Reference><Citation>Domínguez‐Ramírez L, Solis‐Tejeda I, Ayon‐Aguilar J, et al. Decrease in COVID‐19 adverse outcomes in adults during the Delta and omicron SARS‐CoV‐2 waves, after vaccination in Mexico. Front Public Health. 2022;10. doi:10.3389/fpubh.2022.1010256</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2022.1010256</ArticleId><ArticleId IdType="pmc">PMC9513220</ArticleId><ArticleId IdType="pubmed">36176536</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward IL, Bermingham C, Ayoubkhani D, et al. Risk of covid‐19 related deaths for SARS‐CoV‐2 omicron (B.1.1.529) compared with delta (B.1.617.2): retrospective cohort study. BMJ. 2022;378.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9344192</ArticleId><ArticleId IdType="pubmed">35918098</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouzid D, Visseaux B, Kassasseya C, et al. Comparison of patients infected with Delta versus omicron COVID‐19 variants presenting to Paris emergency departments a retrospective cohort study. Ann Intern Med. 2022;175(6):831‐837. doi:10.7326/M22-0308</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M22-0308</ArticleId><ArticleId IdType="pmc">PMC8941485</ArticleId><ArticleId IdType="pubmed">35286147</ArticleId></ArticleIdList></Reference><Reference><Citation>Nordström P, Ballin M, Nordström A. Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID‐19 vaccine: a retrospective, total population cohort study in Sweden. Lancet. 2022;399(10327):814‐823. doi:10.1016/S0140-6736(22)00089-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00089-7</ArticleId><ArticleId IdType="pmc">PMC8816388</ArticleId><ArticleId IdType="pubmed">35131043</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>